Sanofi of­floads two late-stage drugs to vir­tu­al­ly un­known neu­ro and psy­che­del­ic biotech

A fledg­ling New York biotech has man­aged to catch the eye of Sanofi, sign­ing a new col­lab­o­ra­tion with the phar­ma gi­ant to ac­quire two of its pro­grams — but giv­ing away few oth­er de­tails.

Ter­ran Bio­sciences an­nounced the deal in a short press re­lease Thurs­day morn­ing, say­ing very lit­tle about the scope of the pro­grams in­volved or amount of cash chang­ing hands. The on­ly thing the biotech said about the agree­ment was how it in­volved “two late-stage CNS pipeline as­sets.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER